Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term

Hepatology

Volumn 61, Issue 5, 2015, Pages 1503-1511

  Macías, Juan ^a   Mancebo, María ^a   Márquez, Manuel ^b   Merino, Dolores ^c   Téllez, Francisco ^d   Rivero, Antonio ^e   von Wichmann, Miguel A ^f   López Cortés, Luis F ^g   Merchante, Nicolás ^a   Santos, Jesús ^b   Raffo, Miguel ^c   Pérez Pérez, Montserrat ^d   Camacho, Ángela ^e   Iribarren, Jose A ^f   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c Servicio de Cardiología   (Spain)

^d Hospital de la Linea de la Concepcion   (Spain)

^e Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^f HOSPITAL DONOSTIA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE TRACT PARAMETERS; DISEASE CLASSIFICATION; DISEASE COURSE; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS MEASUREMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT RESPONSE; CHRONIC HEPATITIS C; COMPLICATION; LIVER CIRRHOSIS; LIVER FAILURE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84928206990     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27674     Document Type: Article

References (24)

1. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46(3):622-630.
2. Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006;20(1):49-57.
3. Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, et al. Benefits from sustained virological response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013;56(11):1646-1653.
4. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-1206.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-2416.
6. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159(2):86-96.
7. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597-605.
8. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59(3):434-441.
9. Kostman J, Gilmore J, Binkley A, Lynn K, Bahirwani R, Appolo B, et al. Risk of anemia in HIV/hepatitis C virus co-infected patients treated with telaprevir-based hepatitis C virus therapy. Presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 2-6, 2013; Atlanta, GA. Abstract 677.
10. Kohli A, Sims Z, Marti M, Nelson A, Osinusi A, Bon D, et al. Combination oral hepatitis c antiviral therapy for 6 or 12 weeks: final results of the SYNERGY Trial. Presented at: 21st Congress on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA. Abstract 27LB.
11. Rockstroh JK, Nelson M, Soriano V, Arastéh K, Guardiola JM, Bhagani S, et al. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. Presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC. Abstract 1099.
12. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitors of osbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368(1):34-44.
13. Naggie S, Sulkowski MS, Lalezari JP, Fessel J, Mounzer K, Shuhart M, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Presented at: 21st Congress on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA. Abstract 26.
14. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146(2):420-429.
15. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013;18(7):931-940.
16. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010;51(2):585-594.
17. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308(4):370-378.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13(3):372-374.
19. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48(5):835-847.
20. Macías J, Recio E, Vispo E, Rivero A, López-Cortés LF, Ríos MJ, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 2008;49(6):916-922.
21. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343-350.
22. Vergara S, Macías J, Rivero A, Gutierrez-Valencia A, González-Serrano M, Merino D, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007;45(8):969-974.
23. Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Márquez-Solero M, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012;56(1):228-238.
24. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009;49(8):1274-1282.